Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | BRD2 | P25440 | 2/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15890840 | 0.86 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2NPSR1MAPTMEN1 | |
| SCHEMBL532665 | 0.80 | MAPT (0.48) | LMNASMN1; SMN2NPSR1MAPTMEN1 | |
| SCHEMBL533160 | 0.80 | NPSR1 (0.46) | LMNASMN1; SMN2NPSR1MAPTMEN1 | |
| SCHEMBL222904 | 0.80 | NPSR1 (0.46) | LMNASMN1; SMN2NPSR1MAPTMEN1 | |
| SCHEMBL222991 | 0.80 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2NPSR1MAPTMEN1 | |
| SCHEMBL221902 | 0.71 | RAB9A (0.44) | SMN1; SMN2NPSR1MAPTMEN1KMT2A | |
| SCHEMBL224409 | 0.71 | RAB9A (0.44) | SMN1; SMN2NPSR1MAPTMEN1KMT2A | |
| SCHEMBL222151 | 0.69 | BRD4 (0.51) | CYP3A4CYP2C9CYP2C19BRD4BRD2 | |
| SCHEMBL224468 | 0.69 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2NPSR1MAPTMEN1 | |
| SCHEMBL224467 | 0.69 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2NPSR1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | LMNA 4334/4885SMN1; SMN2 2091/4885NPSR1 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.